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Human thymidylate synthase is a homodimeric enzyme that plays
a key role in DNA synthesis and is a target for several clinically
important anticancer drugs that bind to its active site. We have de-
signed peptides to specifically target its dimer interface. Here we
show through X-ray diffraction, spectroscopic, kinetic, and calori-
metric evidence that the peptides do indeed bind at the interface
of the dimeric protein and stabilize its di-inactive form. The “LR”
peptide binds at a previously unknown binding site and shows
a previously undescribed mechanism for the allosteric inhibition
of a homodimeric enzyme. It inhibits the intracellular enzyme in
ovarian cancer cells and reduces cellular growth at low micromolar
concentrations in both cisplatin-sensitive and -resistant cells with-
out causing protein overexpression. This peptide demonstrates the
potential of allosteric inhibition of hTS for overcoming platinum
drug resistance in ovarian cancer.
allosteric mechanism ∣ peptide design ∣ protein–protein interface inhibitor
Enzymes whose catalytic activity depends on multimeric assem-bly are targets for inhibitors that perturb the interactions
between the protein subunits. The high diversity of protein inter-
faces implies opportunities for the identification of specific inhi-
bitors (1–5). The design of peptides and peptidomimetics that
mimic portions of these interfaces has been shown to be a useful
approach for the discovery of inhibitors that bind at protein–
protein interfaces (5–11). However, the inhibitory mechanism
of such ligands is often unclear, and the binding geometry does
not necessarily correspond to that mimicked.
Human thymidylate synthase (hTS) is an enzyme in the folate
pathway that catalyses the reductive methylation of 2′-deoxyuri-
dine-5′-monophosphate (dUMP) to form 2′-deoxythymidine-5′-
monophosphate (dTMP). This methylation reaction is assisted
by the cofactor N5, N10-methylenetetrahydrofolate (mTHF) (12).
hTS is an obligate homodimer whose monomers can adopt active
(A) and inactive (I) forms (13–15). The hTS dimer has two active
sites, each formed by residues from both monomers. Therefore
the dimeric assembly is necessary for the catalytic activity. The
hTS dimer-to-monomer dissociation constant (Kd) was recently
reported to be 200 nM (16). The active and inactive forms differ
in the conformation of the loop from residue 181 to residue 197,
which contains the catalytic cysteine, residue 195. This residue
points into the active site in the active form and toward the dimer
interface in the inactive form (13–15). Active-site inhibitors of
hTS are widely used in chemotherapy; the best known are ralti-
trexed, pemetrexed, and 5-fluorouracil (5FU), a prodrug of the
active 5-fluoro-2′-deoxyuridine-5′-monophosphate (FdUMP)
(17). In addition to its catalytic role, hTS has been shown to reg-
ulate protein synthesis by interacting with its own mRNA as
well as the mRNAs of several other proteins involved in the
cell cycle (18–21). The regulatory function of hTS as an RNA
binding protein has been shown to be maximal when the protein
is ligand-free (22). This observation, together with the observa-
tion that cancer cells resistant to anti-hTS drugs showed
increased levels of hTS, led to the suggestion that the overexpres-
sion of hTS is correlated with the loss of RNA regulatory capacity
when the protein is bound to its inhibitors (19, 21, 23, 24). In the
case of 5FU, a covalent hTS inhibitor, high hTS protein levels
were attributed to both mRNA regulation and a decrease in en-
zyme degradation efficiency caused by inhibitor binding (15, 25).
These studies were performed on colon cancer cells, but clinical
and biochemical observations suggest similar behavior occurs in
other cancer types, such as ovarian cancer. The latter is a severe
pathology with a high mortality rate, which is due to frequent late
diagnosis and the rapid development of drug resistance (26, 27).
Access to therapy has been limited by the cross-resistance of pla-
tinum drugs with classical drugs that target the folate pathway
(28–30). In recent years, clinical trials have demonstrated the
effectiveness of the combination of carboplatin or cisplatin
(cDDP) and pemetrexed, a multitargeted antifolate drug, for
the treatment of platinum-sensitive and -resistant ovarian cancers
(31, 32). Although overexpression of hTS has been observed in
platinum-sensitive cells, this effect is even more pronounced in
platinum-resistant ones. Therefore, it is important to identify
hTS inhibitors that act through new mechanisms that do not alter
RNA regulation or increase protein levels. With this aim, some
diphosphonic acids have been proposed as allosteric inhibitors of
hTS (33). The most active one is 1,3-propanediphosphonic acid
(PDPA) which binds at the position where the phosphate group of
dUMP binds. However, the mechanism of inhibition of these
compounds has not yet been biochemically and mechanistically
demonstrated; furthermore, PDPA has no cellular activity, and
thus its potential as a drug is limited.
In this paper, we describe the discovery of several peptides,
with sequences from the hTS dimer interface, that inhibit hTS
by a mechanism that involves selective binding to a previously
undescribed allosteric binding site at the dimer interface of the
di-inactive form of the enzyme. The mechanism is demonstrated
by X-ray diffraction, CD and fluorescence spectroscopies, kinetic
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analysis, and isothermal titration calorimetry. This mechanism
differs from those of protein–protein interface inhibitors re-
ported to date (5), because it involves stabilization of an inactive
form of the catalytic protein. Unlike the existing drugs targeting
hTS, 5-FU and pemetrexed (34), these peptides inhibit intracel-
lular hTS as well as cell growth without leading to hTS over-
expression when administered to ovarian cancer cells. These pep-
tides are thus promising candidates for the development of more
effective anticancer therapies with reduced potential for drug
resistance development.
Results and Discussion
Peptide Design and Inhibition Kinetics. LcC20 is a 20-mer peptide
with a sequence that corresponds to a β-hairpin structure at
the dimer interface of Lactobacillus casei TS (LcTS). This peptide
destabilizes the protein’s dimeric assembly through an unknown
mechanism and induces aggregation (11). We tested hC20 (resi-
dues 198–217) (Fig. 1A), the corresponding peptide from hTS,
against hTS and measured an IC50 of 30 6 μM. To obtain smal-
ler peptides better suited to the derivation of therapeutic agents,
hC20 was fragmented into seven 8-mers in steps of two amino-
acid residues (Fig. 1B). An additional peptide, C8, which corre-
sponds to residues 247–254 of an adjacent β-strand, was used
to probe a different interface region and does not overlap in
sequence with any of the hC20 interface peptides (35) (Fig. 1A
and SI Appendix).
Kinetic experiments showed that none of the octapeptides
inhibited Escherichia coli TS (EcTS) at concentrations between
0.1 and 2 mM (the concentrations were dependent on peptide
solubility). The hTS enzyme, however, was inhibited by peptides
LN, LR, CG, YS, and C8, with inhibition percentages (I% at
100 μM peptide concentration) between 20 and 85% (Fig. 1B).
In contrast, peptides VQ, QE, and SY were inactive at 100 μM.
LR, CG, and C8 were investigated in more detail by running ki-
netic competition experiments with dUMP and mTHF. Dixon
plots featured straight lines that intersected in the second quad-
rant. For experiments in which dUMP was the competitive
substrate, values of Ki obtained from abscissa intersections in
the mixed-type inhibition model (36) were 26 2, 81 3, and
41 3 μM for LR, CG, and C8, respectively (see Fig. 1C and
SI Appendix). After comparing these results with the sequences
in Fig. 1B, we concluded that the residues close to the N and
C termini of hC20, rather than the residues in the hairpin turn,
were important for the inhibitory activity.
Secondary structure predictions and molecular dynamics
(MD) simulations indicated that all of the octapeptides are flex-
ible and mostly unstructured in aqueous solution (Computational
Studies in SI Appendix). This behavior was confirmed by their
circular dichroism (CD) spectra in water. In the presence of an
increasing percentage of the structure inducer, 2,2,2-trifluoro-
ethanol (TFE), the CD spectra of the peptides that inhibited
hTS (LN, LR, CG, and C8) showed a transition from unordered
structures to features of secondary structure (α-helices and, for
Fig. 1. Peptide design and characterization. (A) Interface location of peptide sequences in the crystal structure of hTS. For clarity, only subunit A of hTS (shown
as a gray surface with ribbons) plus the regions corresponding to the hC20 and C8 peptides of subunit B (shown as rainbow and violet colored highlighted
ribbons, respectively) are shown. (B) Seven octameric peptides (referred to by their first and last residues) were designed to cover the complete sequence of
hC20 with an overlap of six residues. The coloring scheme follows Fig. 1A and measured percentage inhibition values are given. (C) Dixon plot, obtained from
kinetic inhibition studies, showing mixed-type inhibition of hTS in the presence of different concentrations of the LR peptide (I, x-axis) and different con-
centrations of dUMP substrate for the differently coloured lines. (D) The CD spectra of the inhibitory peptides (colored lines) show secondary structure, whereas
the spectra of the inactive peptides (black lines) do not. The spectrum for the YS peptide is shown in gray because, although it shows some inhibitory activity, its
spectrum revealed little secondary structure.
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C8, a polyproline type I helix), whereas the CD spectra of the
inactive peptides (QE, SY, VQ) remained almost unchanged
(Fig. 1D and SI Appendix). The propensity of the eight octapep-
tides to assume secondary structures correlated with their inhibi-
tory activities. Previous studies have shown entropy-mediated
gains in affinity by constraining the conformational freedom of
ligands (37–42). In the present study, spontaneous prestructuring
of the peptide might reduce the entropic penalty associated with
formation of a peptide/hTS complex.
The LR Peptide Binds at a Previously Unknown Binding Site at the
Dimer Interface of hTS in the Inactive Conformation. Crystallization
trials for hTS complexed with the active peptides, LN, LR, CG,
and C8, resulted only in crystals suitable for X-ray crystallography
experiments for the hTS-LR complex. The structure was solved
(Fig. 2A and Table S3 andMethods in SI Appendix) and revealed a
previously undescribed peptide binding site. The electron density
corresponding to the LR peptide spans a cleft located at the inter-
face between the two subunits, which is defined by loops 188–194
of subunit A, the β-strands 175–181 of subunit B, and loops
142–157 of both subunits (hTS 1YPV numbering). The cleft in-
cludes Cys180 and is close to the catalytic Cys195, which points
toward the dimer interface (14, 15). The crystal structures deter-
mined of hTS-LR and of uncomplexed hTS were compared by
least-squares superimposition (PDB ID codes 3N5E and 3N5G,
respectively). The average rmsd of the Cα-atoms between the
LR-complexed structure and the uncomplexed di-inactive struc-
ture was about 0.2 Å. As expected, the largest deviations for the
backbone atoms (1.5–2.0 Å) occurred in the loop regions close to
the LR binding site (e.g., the Cα atoms of Glu145 and Asp148).
Crystallographic refinement showed that the hTS-LR crystals
belonged to the P31 space group rather than the P3121 space
group found in other hTS crystal structures (13). Indeed, the
binding of one LR molecule per hTS dimer destroyed the crystal-
lographic twofold symmetry. The LR peptide was buried in the
binding cleft and covered by the side chains of Met190, Ala191,
and Leu192 of subunit A, which were involved in hydrophobic
interactions with Phe142 and Val158 of subunit B (Fig. 2B). Thus,
the formation of the hTS-LR complex likely requires breathing
movements in the region involved in the binding that controls
the opening and closing of the protein dimer. Superposition
of the present structure with a structure of hTS in an active con-
formation (1HVY) shows that the crevice at the dimer interface
where LR is bound does exist in the active conformation but is
narrower; in the hTS-LR structure, the loop 142–159 is more
open by about 5 Å and the crevice is wider (see Table 1 and
SI Appendix). Furthermore, MD simulations started from an
inactive-uncomplexed form of hTS, show that the interfacial pep-
tide binding site is widened when peptide is bound: The distance
between the two peptide-flanking Trp180 residues increased
by approximately 3 Å in the presence of LR (see Computational
Studies in SI Appendix).
A Previously UndescribedMechanism of hTS Inhibition.The structural
information above suggests that the inhibitory effects of the active
octapeptides might be a result of their ability to stabilize the
di-inactive form of the enzyme, thereby increasing its equilibrium
concentration (14, 15). The possibility that they may act as
dissociative inhibitors can be ruled out because fluorescence
resonance energy transfer (FRET) experiments, performed as
described in ref. 16, show that they do not promote dissociation
of the hTS dimer into monomers (SI Appendix).
To test the inhibition hypothesis given above, the binding of LR
to hTS was characterized by isothermal titration calorimetry
(ITC) (see Fig. 3A). Several binding models were tested (Isother-
mal Titration Calorimetry in SI Appendix) and an excellent fit
(Fig. 3A, Bottom) was achieved with a consecutive, nonidentical,
two-binding-site thermodynamic model in which only one form of
the protein, with an abundance of approximately 1∕3 interacted
with the peptide. The hTS form that was able to bind the peptide
did not interconvert with other protein forms on the time scale of
the experiments (minutes). The best fit values of the thermody-
namic parameters show that while both the enthalpic and the
entropic contributions are large for the first binding site (b1), only
the entropic contribution is large for the second one (b2).
Fig. 2. X-ray crystal structure of the ht-hTS-LR complex. (A) Stereo view of the wholemolecule with the LR peptide (ball and stick representation: carbon atoms
are coral, nitrogen is blue, oxygen is red and sulfur is yellow) bound to the hTS dimer interface. LR is surrounded by the omit map (blue) contoured at 2.5 σ.
Subunits A and B are represented as ribbons, with color ramping from green to red and from violet to blue, respectively. (B) Stereo view reporting a close up of
the omit map (coral wire) contoured at 2.5 σ and superimposed to a ball and stick model of the LR peptide (ball and stick representation as above). The two
independent subunits of hTS are represented as ribbons and cylinders (subunit A: magenta; subunit B: light blue).
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Because of the weaker and entropic nature of the second binding,
crystals of the hTS-LR2 complex may be difficult to obtain (43).
We propose that the octapeptides bind only the di-inactive
form of the protein on the basis of the following evidence: They
do not inhibit EcTS, an enzyme that has never been observed in
an inactive form; crystallographic results show that hTS is in the
di-inactive form when bound to LR; the one-third fraction of the
protein form able to bind the peptide according to the ITC results
in 20 mM phosphate ion solution is consistent with the ca. 0.36 di-
inactive protein fraction corresponding to a 60% abundance of
the inactive form of hTS monomers, estimated from fluorescence
data in this buffer (14, 44), under the assumption that in the
dimeric protein, the probability that a monomer be found in a
particular conformation, whether active or inactive, is indepen-
dent of the conformation of the other monomer. Furthermore,
we did not observe a calorimetric signal when LR was titrated
into an hTS sample that was presaturated with dUMP, consistent
with the fact that dUMP is expected to convert all of the protein
into the active form (44) (SI Appendix). Upon computational
docking of the LR peptide to the hTS dimer, the LR peptide
was found predominantly at the dimer interface. While a docking
pose was found close to the crystallographically observed site in
the di-inactive form, docking poses were also found on the oppo-
site side of the dimer interface (SI Appendix). The docking results
thus support the hypothesis that two peptides could bind to dif-
ferent sites at the dimer interface of the inactive conformation
of hTS.
The results from X-ray crystallography, computational model-
ing, and calorimetry provide evidence for a previously unde-
scribed allosteric inhibitory mechanism for hTS. We propose the
kinetic scheme shown in Fig. 3B for the interaction of LR with
hTS. This is a special case of a more general mechanistic scheme
provided in Analysis of the kinetics of hTS inhibition by LR in SI
Appendix. In the general scheme, the enzyme is assumed to take
several different forms, some of which are catalytically inactive
and can bind ligands that contribute to their stabilization.
According to the kinetic scheme in Fig. 3B, the peptide only binds
the di-inactive form of the enzyme and stabilizes it. Analysis of
this mechanism yields the Dixon-plot equation in Fig. 3B (see SI
Appendix for a derivation). In this scheme, S is the concentration
of dUMP (the variable-concentration substrate), and the protein
is assumed to be presaturated with the mTHF substrate. The
equation describes a family of straight lines that cross in the sec-
ond quadrant and is therefore fully consistent with the inhibition
pattern exhibited by LR (Fig. 1C), CG, and C8 (SI Appendix).
From the intersection of the plot for LR, (½Li ¼ −½K4ðK1þ
K2Þ þ K1K3∕K1K3K5 and v−1i ¼ vmax−1), and the kinetic data
analysis outlined in SI Appendix, we obtained vmax ¼ 0.22
0.04 μM∕s, which corresponds to the catalytic constant,
k ¼ 0.8 0.15 s−1. Assuming K1, K2, K3, and K4 in Fig. 3B have
the same value, K , we estimated this value to be approximately
K ¼ 1 × 105 M−1ðK−1 ∼ 10 μMÞ. These parameters are compar-
able with the catalytic rate constant and KM values obtained
in the absence of inhibitor (i.e., k ¼ 0.9 0.2 s−1 and KM ¼ 11
1 μM). Furthermore (see SI Appendix), we estimate a value of
K5 ¼ 1.1 × 105 M−1 for LR peptide binding (dissociation con-
stant, K5
−1 ∼ 10 μM). This value for K5 is more than one order
of magnitude lower than the first binding constant, Kb1, obtained
from ITC (Kb1 ¼ 6.6 × 106 M−1, Kd1 ¼ 151 nM). The discussion
of the consistency of this inhibition mechanism with the ITC
model is complex. The mechanism requires a fast active-
inactive interconversion for inhibition to occur. On the other
hand, the ITC model requires that the active-inactive intercon-
version be slow compared with the ITC time scale. An important
difference between the kinetic and calorimetric experiments is
that, to avoid the catalyzed reaction, calorimetric titrations with
Fig. 3. hTS-LR peptide binding thermodynamics and proposedmechanism of hTS inhibition. (A) Top: Raw data from ITC experiments at 25 °C showing the heat
flux recorded for each titration. Bottom: ΔH-vs-r plot where ΔH is the cumulative enthalpy (sum of the peak areas in the top panel) expressed per mole of
protein and r is the concentration ratio of total titrated ligand to total protein. The red line represents the best fit of the experimental data (circles) using a
thermodynamic model with two species of the protein with a constant population ratio, one of which presents two consecutive binding sites. A fixed stoi-
chiometry of one ligand per binding site was assumed. Errors are within 10% of the reported values. The thermodynamic data for the first and second binding
sites, respectively, are: Kb1 ¼ 6.6 × 106 M−1ðKd1 ¼ 151 nMÞ, ΔH1 ¼ −12.3 kJ∕mol, TΔS1 ¼ 26.6 kJ∕mol, ΔG° ¼ −38.9 kJ∕mol1, and Kb2 ¼ 7.8 × 105 M−1
ðKd2 ¼ 1.3 μMÞ, ΔH2 ¼ −3.1 kJ∕mol, TΔS2 ¼ 30.5 kJ∕mol, ΔG° ¼ −33.6 kJ∕mol2. (B) Schematic diagram of the proposed mechanism of hTS inhibition in which
the dimeric protein is represented by active (light blue) and inactive (magenta) subunits that interact with the substrate (S≡ dUMP, green) and the inhibitor
(L≡ peptide, orange). The fractions of free monomers, of di-active protein with both active sites occupied by a substrate, and of di-inactive protein with two L
molecules bound are assumed to be negligible.
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dUMP were carried out in the absence of mTHF. Therefore, con-
sistency of the proposed kinetic and calorimetric models relies on
the assumption that mTHF accelerates the active-inactive inter-
conversion, making it quicker than the time scale of the kinetic
experiments.
Peptides Inhibit hTS in Ovarian Cancer Cells Without Resulting in hTS
Protein Overexpression. The peptides that were active in the enzy-
matic kinetic assays (LN, YS, LR, CG, and C8) were tested
against hTS in cellular extracts from untreated cells. Although
LN and CG displayed little or no inhibition of enzyme activity in
the cDDP-sensitive and -resistant cell extracts (inhibition range
10–35%), YS, C8, and LR showed higher inhibitory activity
against the enzyme in both cell lines (inhibition range 50–70%)
comparable with the I% against the recombinant protein that was
(I% at 100 μM peptide concentration) between 20 and 85%. The
peptides alone did not enter the cells. To test their effects on cell
growth, we employed a delivery system that we checked did not
alter cell growth itself. Administration of 5–10 μM of YS, C8, or
LR (the peptides most active against hTS in cell extracts) signif-
icantly (*P < 0.05, n ¼ 5) inhibited the growth of all cell lines
by about 50% (SI Appendix). The YS and LR peptides appeared
particularly active against A2780 cells.
Of these active peptides, we focused on LR because of the
availability of crystallographic information on its complex with
hTS. At 5 and 10 μM, LR inhibited the growth of both sensitive
and resistant cell lines by approximately 50% after both 48- and
72-h exposures (Fig. 4). A higher cell death was caused by 10 μM
LR for the A2780 line. With the latter cell line and its resistant
counterpart, LR turned out to be more effective than 5-FU at the
same concentration (Fig. 4B).
Information on the mode of action of these peptides in cells
was provided by measurement of the inhibition of cellular hTS
and of protein and mRNA transcript levels. Upon incubation
with ovarian cancer cells, LR inhibited the intracellular enzyme
activity quite markedly, though less efficiently than 5-FU; the
effect was more pronounced in the sensitive cells (Fig. 5A).
To verify whether an impairment of intracellular enzyme activ-
ity and of cell growth was reflected by the levels of enzyme ex-
pression (Fig. 5B) and RNA (Fig. 5C), these were determined
under the same experimental conditions. The total hTS protein
level was increased by 5-FU exposure in both cell lines, which has
been suggested to be due to the formation of the inactive ternary
complex hTS-FdUMP-mTHF (45). In contrast, 20 μM LR de-
creased the total hTS protein level by about 25% in sensitive cells
and did not affect the protein level in the resistant cells (Fig. 5B).
The level of hTS mRNA was about the same in the presence of
both LR and 5-FU in resistant cells while it was higher in sensitive
cells (Fig. 5C). The overexpression of hTS mRNA in sensitive
cells likely resulted from a transcriptional induction following
the downstream inhibition of TS protein. LR also decreased
the level of dihydrofolate reductase (DHFR), another important
enzyme in the folate pathway (46), although not as markedly as
5-FU (Fig. 5B). Interestingly, LR did not inhibit the hDHFR
recombinant protein. The LR-induced decrease in hDHFR levels
in the cells might result from a decrease of the dihydrofolate
levels due to hTS inhibition.
Conclusions and Perspectives. We have identified several octapep-
tides that inhibit hTS. Of these, LR binds at a previously uniden-
tified binding site located at the interface between the two
monomers of the hTS homodimer and inhibits hTS by a pre-
viously undescribed mechanism of action. Rather than acting
as a dissociative inhibitor, LR stabilizes the di-inactive form of
the protein. The peptides that inhibit hTS have an inducible sec-
ondary structure and inhibit the growth of both cisplatin-sensitive
and cisplatin-resistant ovarian cancer cell lines. In contrast to
classical TS inhibitors (e.g., 5-FdUMP and pemetrexed), the pep-
tides inhibit intracellular TS without inducing its overexpression.
The connection between the stabilization of the inactive form
of hTS by LR and the cellular effects remains to be fully explored.
Further steps will require optimization of the compounds by
synthesis of peptidomimetics and detailed analysis of their cellular
mechanism of action. To our knowledge, this is a unique demon-
stration of a mechanism in which a multifunctional homodimeric
protein is inhibited through binding of a ligand to the dimer inter-
face of the di-inactive conformation of the enzyme, resulting in
stabilization of this form. We believe that the concepts revealed
here can be exploited to provide new avenues for the development
of drugs for combating severe diseases such as ovarian cancer.
Methods
Chemicals and Peptides. hC20 and LR peptides were synthesised by an auto-
matic solid phase peptide synthesiser (Syro XP II, Multisyntech) using Fmoc/
tBu chemistry (47). The peptides were cleaved from the resin using reagent B
(48). Crude peptides were purified by preparative reverse-phase HPLC, and
the purity grade was checked by analytical HPLC analyses and mass spectro-
metry (seeMethods in SI Appendix). All other peptides employed in this study
were purchased from GeneCust (www.genecust.com). The level of purity of
peptides was >95%. The peptides were further purified before use to remove
trifluoroacetic acid residues. dUMP and mTHF were purchased from Sigma-
Aldrich.
Protein Cloning and Purification. hTS was purified from the E. coli BL21 strain
DH5α transformed with pQE80L, which contained the complete coding
sequence for the hTS tagged with a histidine tail (ht-hTS). Purification
involved sequential chromatography on an Ni Sepharose 6 Fast Flow resin
Fig. 4. Inhibition of cell growth by the LR peptide and 5FU for cDDP-sensitive and -resistant cells. (A) 2008 and C13* cells; (B) A2780 and A2780/CP cells. The
concentration of LR (red) or 5-FU (blue) is given on the x-axis in μM. The LR Peptide was transfected into cells via a peptide delivery system. Cell survival
percentages are the mean S:E:M: of at least three separate experiments performed in duplicate. Results were analyzed with Student t tests. *P < 0.05 com-
pared with control cells.
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column and a HiTrap desalting column, which were both purchased from GE
Healthcare (www.gehealthcare.com). EcTS was purified through ammonium
sulphate precipitation and sequential chromatography using DEAE
Sephacel and Phenylsepharose CL-4B resin. The protein concentrations
were determined spectrophotometrically from absorbance at 280 nm
(ϵ280 ¼ 89;000 M−1 cm−1).
Enzyme Kinetics. Various concentrations of peptides were incubated with hTS
and EcTS in phosphate buffer (pH 6.9) at 25 °C. Aliquots of the enzyme were
assayed for activity under standard conditions: An aliquot of TS (0.5–1 μg) was
added to 1 mL of assay buffer consisting of 50 mM TES (pH 7.4) containing
25 mMMgCl2, 6.5 mMHCHO, 1 mM EDTA, 75 mM β-mercaptoethanol (β-ME),
0.120 mM dUMP, and 0.15 mM mTHF. Following addition of the enzyme, the
absorbance was monitored at 340 nm for 4 min.
Circular Dichroism. CD spectra were recorded on a JASCO-J-810 spectropolari-
meter in quartz cells with path lengths of either 0.1 or 1 cm using the follow-
ing parameters: 4 s response; 50 nm∕min scan speed; 0.1 nm data pitch; 2
accumulations; 1 nm bandwidth. Spectra were corrected by subtracting
the cell and solvent contributions and were smoothed using a standard noise
reduction routine provided with the instrument. Stock peptide solutions ap-
proximately 500 μM were prepared in pure Milli-Q water or pure TFE. The
peptide concentrations were checked spectrophotometrically using the max-
imum molar extinction coefficient values for Tyr (ϵ ¼ 1440 M−1 cm−1 at
274 nm) and Phe (ϵ ¼ 220 M−1 cm−1 at 257 nm). All spectra were measured
within half an hour from solution preparation.
Crystallography. The histidine-tagged construct (ht-hTS) consisted of the com-
plete sequence of hTS (SwissProt entry: P04818) with the MRGSHHHHHHGS
sequence added at the N terminus, which resulted in a total of 325 amino-
acid residues and a molecular weight of 37,114 Da. ht-hTS has a dimeric qua-
ternary structure, which was indicated by gel-filtration chromatography and
confirmed by crystal structure determination. Crystals of ht-hTS were ob-
tained using a sitting drop setup using as precipitant a 20–25% saturated
ðNH4Þ2SO4 buffered at pH 8.3 (see SI Appendix for details). Crystals of the
ht-hTS complex with the LR peptide (LSCQLYQR; ht-hTS-LR) were grown in
the same setup and precipitant conditions from a ht-hTS solution incubated
for 2 h at 4 °C with a 1 mM solution of the LR peptide in water (see SI
Appendix for details). The ht-hTS and ht-hTSLR crystals displayed the same
habit and belong to the trigonal system. Crystallographic data were collected
at 100 K on frozen crystals upon cryoprotection. The data collection was per-
formed at ESRF (Grenoble) on beamlines ID 14-1 and ID 23-1.The crystals were
stable in the beam over the data collection time (approximately 25 min), and
one crystal was used for each dataset. See SI Appendix and Table S3 in SI
Appendix for details and final data collection statistics. The two structures
were solved using the molecular replacement technique (49) using as model
one subunit of human TS (50) (PDB ID code 1YPV) for ht-hTS and using ht-hTS
as model for the ht-hTS-LR complex. The refinement was carried out by using
REFMAC5 (51). Between the refinement cycles, the models were subjected to
manual rebuilding using Xtal (52) and Coot (53). The program Coot has been
used to model the LR peptide. The structure of ht-hTS belongs to the trigonal
space group P3121where the twofold axis of the ht-hTS dimer coincides with
the crystallographic twofold axis. The formation of a 1∶1 complex between
the ht-hTS dimer and the LR peptide should remove the twofold symmetry
present in the enzyme. In order to ascertain if the symmetry of the ht-hTS-LR
crystal was effectively lowered to P31, we processed and refined the data in
both P3121 and P31 space groups. The final Rcryst and Rfree factors converged
to lower values for the structure in P31 indicating that ht-hTS-LR belongs to
this space group. Additional details about structure solution and refinement
are reported in SI Appendix and the refinement statistics are shown in
Table S3 in SI Appendix.
Fluorescence. Fluorescence resonance energy transfer experiments were car-
ried out on hTS difunctionalized with an excitation-energy donor, fluorescein
(F), and an acceptor, tetramethyl rhodamine (T). The protocol employed to
conjugate the two probes to the dimeric protein, the structural aspects
Fig. 5. Effects of LR and 5-FU on hTS and DHFR protein levels, hTS mRNA levels and hTS activity in two ovarian cancer cell lines. (A) Western immunoblot
analysis of hTS (above) and DHFR (below) protein levels from 2008 and C13* cells treated for 72 h with the indicated concentrations of 5-FU (blue) and LR
peptide (red). The latter was administered via a peptide delivery system. The 35-kDa hTS monomer, with or without its ternary complex, and the 21-kDa hDHFR
monomer are reported below the bar graphs of their respective densitometric analyses. Western blot analyses were performed on cytosolic extracts from cells
in the exponential phase of growth using anti-hTS and DHFR monoclonal antibodies. Each experiment was carried out three times, and a representative result
is shown. An antihuman ß-tubulin mouse antibody was used to verify equal protein loading in the gel. (B) RT-PCR analysis of hTS mRNA levels. hTS expression in
2008 and C13* cells extracts was determined after treatment with the LR peptide or 5-FU for 72 h. The amount of hTS mRNA was normalized by the mRNA of
glyceraldehyde-3-phosphate dehydrogenase. The results shown are the means S:E:M: of four separate experiments performed in duplicate. (C) Inhibition of
intracellular TS activity.
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(the two probes bind at C43 and C43′) and the quantitative analysis of the
steady-state fluorescence data are described in detail in ref. 16. Solutions of
the diconjugated protein in phosphate buffer, pH 7.5, were checked at the
UV-visible spectrophotometer (Varian Cary 100) to contain comparable con-
centrations (typically ca. 350 nM) of each of the two probes, F and T, and of
protein dimers. Emission spectra at λexc ¼ 450 nm of these solutions were re-
corded at different peptide concentrations on a Jobin-Yvon Fluoromax2 spec-
trofluorometer and were corrected for the instrumental spectral sensitivity.
Isothermal Titration Calorimetry. The calorimetric experiments were per-
formed on a MicroCal® (www.microcal.com) VP-ITC MicroCalorimeter. The
enzyme solution was thawed on the day of experiment and its concentration
was checked spectrophotometrically at 280 nm. It was then degassed for
8 min under magnetic stirring, filtered with a 0.45 μm filter, and loaded inside
the sample cell of the instrument. 8-mer peptides were dissolved in experi-
mental buffer at the desired concentration the day before the experiment
and the solutions were left under magnetic stirring at 4 °C. The solutions
were filtered with a 0.45 μm filter and loaded in the injection syringe.
Experiments were initiated by filling the reference cell with 1.5 mL of
double distilled Milli-Q water and the sample cell with 1.5 mL of hTS solution
(10, 20, and 40 μM) in phosphate buffer (20 mM NaH2PO4, 30 mM NaCl,
pH 7.5). Titration of LR (1 mM) was carried out at 298 K via a rotating stir-
rer-syringe. The injection volume was 10 μL and an equilibrium time of 4 min
was allowed between each injection. The total number of injections was 25.
Blank titrations were performed by injecting the ligand into the buffer
devoid of protein to correct for the heat of mixing and ligand dilution. This
contribution to the observed heat of reaction was subtracted from the cor-
responding total heat. The heat arising from enzyme dilution due to titrant
injection was negligible in all cases. See SI Appendix for data analysis. For the
titration of LR against the hTS-dUMP complex, 0.052 mM solution of hTS
in phosphate buffer was incubated for 1 h with dUMP at saturating concen-
trations (3,000 μM) prior to the titration.
Computational Methods. The helical content of the peptides was predicted
with the AGADIR algorithm (54). MD simulations were carried out of peptides
and hTS-peptide complexes in water with the AMBER simulation package
(55) using the AMBER ff03 forcefield (56). Peptides were docked to hTS with
the programGOLD (57) using the ChemScore scoring function. For details, see
Methods in SI Appendix.
Experiments with Cells. The 2008 cell line was established from a patient with
serous cystadenocarcinoma of the ovary. The cDDP-resistant C13* subline,
approximately 15 times more resistant to cDDP than a normal cell line,
was derived from the parent 2008 cell line as previously reported (58).
The human ovarian carcinoma A2780/CP cells were 12-fold resistant to cDDP
and derived from the parent A2780 cell line. Peptides were delivered into
cells via the SAINT-PhD peptide delivery system (Synvolux Therapeutics
B. V.). Cells that were used for the enzyme assay were treated according
to procedures published by van Triest et al. (59). The crystal violet dye assay
was performed on a cell monolayer (60). Western blot analysis on TS and
DHFR proteins was conducted as previously described (61). Reverse transcrip-
tion was performed with 2 μg of total RNA, and RT-PCR was performed with
10 ng of cDNA using the Power SYBR® Green PCR Master Mix (Applied Bio-
systems). This was followed by a dissociation curve analysis and agarose gel
electrophoresis to confirm the amplification (62). Statistical significance was
estimated by a two-tailed Student’s t test using Microsoft Excel. A P value
<0.05 was considered significant.
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